Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and infliximab [review]) for Crohn's disease (review of TA40)

This guidance replaces 'NICE technology appraisal guidance 40' issued in April 2002.

The review and re-appraisal of infliximab for the treatment of severe active or active fistulising Crohn’s disease has resulted in a change in the guidance. Specifically, infliximab should now be given as a planned course of treatment until treatment failure (including the need for surgery) or for 12 months, whichever is shorter. Treatment should then only be continued if there is clear evidence of ongoing active disease. Adalimumab is now also recommended as another treatment option for people with severe active Crohn’s disease.

• Other information

  • TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40): guidance web format

  How this guidance was produced

  Background information

  • Crohn's disease - infliximab (review) and adalimumab: review decision - March 2011
  • Review Proposal - January 2011
  • Appendix A: provisional matrix of stakeholders
  • Appendix B: proposal paper presented to the Institute's Guidance Executive
  • NICE recommends two more treatments for Crohn's disease

Guidance formats

• Web format
• Quick reference guide (PDF)
• Full Guidance (PDF)
• Patient version (MS Word)
• TA187 Infliximab ac adalimumab ar gyfer afiechyd Crohn: deall canllawiau NICE (fformat MS Word)

Crohn's disease - infliximab (review) and adalimumab (review of TA40)

Guideline for patients and carers (PDF)